Tag Archives: RVNC

Mizuho Securities Keeps a Buy Rating on Revance Therapeutics (RVNC)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Revance Therapeutics (RVNC – Research Report) yesterday and set a price target of $35.00. The company’s shares closed last Tuesday at $20.03. According to TipRanks.com, Yang has 0 stars on

Stifel Nicolaus Maintains Their Buy Rating on Revance Therapeutics (RVNC)

Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Revance Therapeutics (RVNC – Research Report) today and set a price target of $31.00. The company’s shares closed last Thursday at $14.94. According to TipRanks.com, Samimy is a 4-star analyst

Needham Sticks to Its Buy Rating for Revance Therapeutics (RVNC)

In a report released today, Serge Belanger from Needham maintained a Buy rating on Revance Therapeutics (RVNC – Research Report), with a price target of $36.00. The company’s shares closed last Tuesday at $15.96. According to TipRanks.com, Belanger is a

Revance Therapeutics (RVNC) Gets a Buy Rating from Mizuho Securities

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Revance Therapeutics (RVNC – Research Report), with a price target of $35.00. The company’s shares closed last Tuesday at $14.80. According to TipRanks.com, Yang has

William Blair Remains a Buy on Revance Therapeutics (RVNC)

In a report released today, Tim Lugo from William Blair maintained a Buy rating on Revance Therapeutics (RVNC – Research Report). The company’s shares closed last Monday at $15.27. According to TipRanks.com, Lugo is a 2-star analyst with an average

Revance Therapeutics (RVNC) Gets a Buy Rating from Needham

Needham analyst Serge Belanger maintained a Buy rating on Revance Therapeutics (RVNC – Research Report) on February 24 and set a price target of $36.00. The company’s shares closed last Monday at $24.76. According to TipRanks.com, Belanger is a 4-star